SCHEMBL21962676

SCHEMBL21962676

CN(Cc1ccc(S(=N)(=O)N[Si](C)(C)C(C)(C)C)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.37
SLC6A4 P31645 2/20 0.37
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
GLS O94925 1/20 0.35
LIMK2 P53671 5/20 0.34
ABL1 P00519 1/20 0.34
LCK P06239 1/20 0.34
LIMK1 P53667 1/20 0.34
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
CTSS P25774 1/20 0.34
ADRB3 P13945 1/20 0.34
MMP13 P45452 2/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26007609 0.88 LIMK2 (0.40) HTR2CSLC6A4GLSLIMK2ABL1
SCHEMBL16629508 0.80 HTR2C (0.40) HTR2CSLC6A4HDAC3HDAC1HDAC2
SCHEMBL20692403 0.77 SCN3A (0.38) HTR2CSLC6A4GLSCACNA1GCACNA1B
SCHEMBL20681015 0.76 CA2 (0.50) CA2
SCHEMBL21810636 0.75 HTR2C (0.35) HTR2CSLC6A4GLSCTSLCTSB
SCHEMBL26007608 0.75 HTR2C (0.37) HTR2CSLC6A4HDAC3HDAC1HDAC2
SCHEMBL2229917 0.74 MTOR (0.48) HTR2CSLC6A4HDAC3HDAC1HDAC2
SCHEMBL17544325 0.74 HDAC3 (0.39) HTR2CSLC6A4HDAC3HDAC1HDAC2
SCHEMBL21893848 0.73 LIMK2 (0.43) LIMK2ABL1LCKLIMK1
SCHEMBL22012877 0.73 GLS (0.36) HTR2CSLC6A4GLSLIMK2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3880659-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2021-09-22 EP disclosed
WO-2020102576-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed